Dr. Chen received a B.S. degree in Biology from the Massachusetts Institute of Technology (1990), a Ph.D. in Microbiology & Immunology (1996) and M.D. (1998) from the University of Southern California. Daniel completed an Internal Medicine Residency and Medical Oncology Fellowship at Stanford University (2003). He went on to complete a postdoctoral fellowship with Mark Davis in Immunology, where he was a Howard Hughes Medical Institute Associate. He also ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003-2006, where he continues to care for melanoma patients. In that time, he studied human anti-cancer immune responses pre- and post-cancer vaccination and cytokine administration to determine why anti-tumor immune responses were not more clinically effective. He received a U19 grant to develop better immunologic tools to interrogate human immune responses and ultimately patented the MHC cellular microarray to detect and functionally characterize antigen-specific T cell states. Since joining Genentech in 2006, Daniel has focused on the clinical development of anti-angiogenic and immune modulatory targeted therapies in both early and late development, as well as the diagnostic tools to aid their development. He is a reviewer for Nature, Immunity, and Clinical Cancer Research, co-chair of the CRI Cancer Immunotherapy Consortium and gave the keynote presentation at the AACR NCI EORTC Annual Meeting 2014. He has continued to publish with academic and Genentech collaborators in the field of cancer immunotherapy, including the often referenced Chen and Mellman manuscript, “Oncology meets Immunology: the Cancer-Immunity Cycle.”
Session Abstract – PMWC 2017 Silicon Valley
As immunotherapies becomes a backbone of cancer treatment, biomarker assays will be critical to optimizing the use of immunotherapies as single agent or in combinations. This panel will explore how leading biopharma and academic researchers are identifying biomarkers and developing companion diagnostics for immuno-oncology.